Ozempic and Gastroparesis: What the FDA Safety Review Reveals About Causation Evidence
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Messaging to Targeted Risk Communication
If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering whether the medication could be causing gastroparesis. The scientific community has long emphasized the importance of evidence-based safety assessments for widely prescribed drugs. This page reviews the current FDA safety data and explains what causation evidence can and cannot establish, helping you organize your own symptom timeline and medical records.
Bridging General Awareness to Specific Clinical Evidence
The following discussion examines the evidence linking Ozempic use to gastroparesis risk, moving from general awareness to specific clinical considerations. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, abdominal pain, and constipation. These reactions are common and often occur during dose escalation. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Gastroparesis: Symptoms, Diagnosis, and Overlap with Ozempic Side Effects
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Its clinical presentation includes early satiety, postprandial fullness, nausea, vomiting, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath testing. The symptoms of gastroparesis overlap with the gastrointestinal adverse reactions reported with Ozempic, such as nausea, vomiting, and abdominal pain. In placebo-controlled trials, nausea was reported in 15.8% of patients on Ozempic 0.5 mg and 20.3% on Ozempic 1 mg, compared to 6.1% on placebo; vomiting occurred in 5.0% and 9.2% of Ozempic-treated patients, respectively, versus 2.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Abdominal pain was reported in 7.3% (0.5 mg) and 5.7% (1 mg) of Ozempic-treated patients, compared to 4.6% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Constipation was also noted, with rates of 5.0% (0.5 mg) and 3.1% (1 mg) versus 1.5% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying as part of their pharmacodynamic effect. This delay in gastric emptying is a known action of GLP-1, which contributes to postprandial glucose regulation. However, excessive or prolonged slowing can lead to symptoms consistent with gastroparesis.
FDA Warnings and Causation Considerations
The prescribing information for Ozempic lists serious adverse reactions including pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant use of insulin secretagogues or insulin, acute kidney injury, hypersensitivity, and acute gallbladder disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is not explicitly listed as a serious adverse reaction in the prescribing information, but the gastrointestinal symptoms that are reported—nausea, vomiting, abdominal pain—are core features of gastroparesis. The adequacy of warnings regarding Ozempic and gastroparesis is a matter of risk communication. The prescribing information does not specifically warn about gastroparesis as a distinct adverse reaction, though it does warn about gastrointestinal adverse reactions in general. The most common adverse reactions reported in ≥5% of patients treated with Ozempic are nausea, vomiting, diarrhea, abdominal pain, and constipation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For patients who develop persistent or severe gastrointestinal symptoms, the differential diagnosis should include gastroparesis. Causation considerations for affected patients involve the temporal relationship between Ozempic initiation and symptom onset. The majority of gastrointestinal adverse reactions occur during dose escalation, suggesting a dose-dependent effect. In clinical trials, gastrointestinal adverse reactions were more frequent with higher doses (2 mg vs 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The timeline between exposure and documented harm can vary, but symptoms often emerge within weeks of starting treatment or increasing the dose. For patients experiencing symptoms suggestive of gastroparesis while on Ozempic, clinical evaluation should include assessment of gastric emptying. Discontinuation of Ozempic may lead to resolution of symptoms, though this is not guaranteed. The prescribing information notes that more patients on Ozempic discontinued treatment due to gastrointestinal adverse reactions compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the pool of placebo- and active-controlled trials and in the 2-year cardiovascular outcomes trial, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). No new safety signals were identified in a 40-week trial with 959 patients treated with Ozempic 1 mg or 2 mg as add-on to metformin with or without sulfonylurea (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In summary, while Ozempic is associated with gastrointestinal adverse reactions that overlap with gastroparesis symptoms, the prescribing information does not specifically warn about gastroparesis. Patients and clinicians should be aware of the potential for delayed gastric emptying and monitor for persistent gastrointestinal symptoms. Causation assessment requires consideration of temporal association, dose relationship, and exclusion of other causes. The evidence from clinical trials indicates a dose-dependent increase in gastrointestinal adverse reactions, with higher rates of discontinuation compared to placebo.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the FDA warning about Ozempic and gastroparesis?
The FDA prescribing information for Ozempic does not explicitly list gastroparesis as a serious adverse reaction, but it warns about gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, abdominal pain, and constipation, which are core symptoms of gastroparesis. The label notes that these reactions are dose-dependent and more common during dose escalation. Patients experiencing persistent gastrointestinal symptoms should be evaluated for gastroparesis.
How can Ozempic cause gastroparesis?
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism to regulate postprandial glucose. In some individuals, this effect can become excessive or prolonged, leading to symptoms consistent with gastroparesis, such as early satiety, nausea, vomiting, and abdominal pain. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions, with higher rates at 2 mg compared to 1 mg.
What should I do if I develop gastroparesis symptoms while taking Ozempic?
If you experience persistent or severe gastrointestinal symptoms such as nausea, vomiting, bloating, or abdominal pain while on Ozempic, consult your healthcare provider. They may recommend diagnostic tests like gastric emptying scintigraphy to evaluate for gastroparesis. Depending on the assessment, your doctor may adjust the dose or discontinue Ozempic. Symptoms may resolve after stopping the medication, but not always.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.